Jury Finds Takeda Delayed Generic Constipation Drug Competition

What’s happening

A U.S. jury found that Takeda Pharmaceutical Company participated in an antitrust scheme that delayed cheaper generic versions of a constipation drug.

What’s changing / Business impact

Increased legal pressure on:

• pharmaceutical pricing strategies
• patent protection tactics

Greater scrutiny around delayed generic competition.

Why this matters

Generic drugs are usually much cheaper than branded medicines.

This shows:

• governments and courts are challenging pharma tactics that delay cheaper alternatives
• drug pricing battles remain a major issue in U.S. healthcare